Abstract 33P
Background
Evidence highlights the critical role of CD4 T cells in antitumor immunity and immunotherapy. We previously reported that baseline or post-treatment hTERT-specific CD4 Th1 response in blood is associated with the efficacy of immune checkpoint inhibitors (ICI) therapy in patients with advanced melanoma and colorectal cancer (Nardin et al, 2021; Thibaudin et al, 2022). Here, we investigated the involvement of peripheral tumor reactive CD4 Th1 response in durable response to ICI in melanoma patients.
Methods
Blood samples were collected in three groups of advanced melanoma (AJCC8 stage III/IV) patients (pts) according to response to ICI: 50 pts with prolonged disease control (>1 year) (CD[FA1]), 22 pts with primary resistance (R1) defined as no response after 3 months of ICI, and 35 pts with relapsed disease after treatment discontinuation for initial disease control (>1 year) (R2). Multiparametric immunologic analyses were performed using IFN-γ ELISpot, flow cytometry on PBMC and Bulk RNA sequencing on circulating sorted CD4 T cells.
Results
A high frequency of circulating tumor-specific CD4 Th1 response, i.e response against at least one of the 3 antigens tested (hTERT, MAGE-A3 and KK-LC1), was found in all 3 groups (76%, 63%, 68% in CD, R1, R2, respectively). Among the 3 antigens tested, the circulating hTERT-specific CD4 Th1 response frequency was higher in CD compared to R1 and R2 : 70% vs 25% vs 40% positive response (**, p<0.01). Furthermore, CD4 Th1 polyspecific responses, i.e against at least 2 of the 3 antigens tested were more detected in CD pts (31 pts, 62%) compared to 15 (42%) and 7 (32%) pts in R2 and R1 respectively. hTERT-specific CD4 Th1 exhibits cytotoxic phenotype and a modified memory profile compared to non-specific CD4 T cells. Transcriptomic analyses of CD4 T cells revealed 669 genes upregulated and 52 down-regulated in CD pts, mainly enriched in Th1-associated pathways such as IFN-γ response, TNF-α signaling via NF-κB and IL-2-STAT5 signaling compared to healthy donors. Analyses of immune-related genes showed upregulation of cytotoxic markers in CD pts compared to R1 and R2.
Conclusions
In conclusion, our data demonstrated that cytotoxic hTERT-specific CD4 Th1 response is involved in the long-term response to ICI.
Legal entity responsible for the study
CHRU Besançon.
Funding
La ligue contre le cancer; Bourse Chrysalide.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract
53P - Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Presenter: Saket Srivastava
Session: Poster Display session
Resources:
Abstract